A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome.
Identifieur interne : 001560 ( PubMed/Curation ); précédent : 001559; suivant : 001561A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome.
Auteurs : A D Krahn [Canada] ; G J Klein ; R. YeeSource :
- Pacing and clinical electrophysiology : PACE [ 0147-8389 ] ; 2001.
English descriptors
- KwdEn :
- Adolescent, Adult, Anti-Arrhythmia Agents (administration & dosage), Anti-Arrhythmia Agents (therapeutic use), Atrial Fibrillation (drug therapy), Atrial Fibrillation (etiology), Double-Blind Method, Electrophysiologic Techniques, Cardiac, Humans, Infusions, Intravenous, Male, Middle Aged, Phenethylamines (administration & dosage), Phenethylamines (therapeutic use), Pilot Projects, Sulfonamides (administration & dosage), Sulfonamides (therapeutic use), Tachycardia, Atrioventricular Nodal Reentry (drug therapy), Tachycardia, Atrioventricular Nodal Reentry (etiology), Wolff-Parkinson-White Syndrome (complications), Wolff-Parkinson-White Syndrome (drug therapy).
- MESH :
- chemical , administration & dosage : Anti-Arrhythmia Agents, Phenethylamines, Sulfonamides.
- chemical , therapeutic use : Anti-Arrhythmia Agents, Phenethylamines, Sulfonamides.
- complications : Wolff-Parkinson-White Syndrome.
- drug therapy : Atrial Fibrillation, Tachycardia, Atrioventricular Nodal Reentry, Wolff-Parkinson-White Syndrome.
- etiology : Atrial Fibrillation, Tachycardia, Atrioventricular Nodal Reentry.
- Adolescent, Adult, Double-Blind Method, Electrophysiologic Techniques, Cardiac, Humans, Infusions, Intravenous, Male, Middle Aged, Pilot Projects.
Abstract
Pharmacological conversion of arrhythmias in Wolff-Parkinson-White (WPW) syndrome is often frequently undertaken. Current antiarrhythmic drugs used for conversion can be associated with significant side effects and variable efficacy. Fifteen male patients (mean age 34, range 18-63 years) with WPW syndrome and atrial fibrillation or AVRT induced in the electrophysiology laboratory were enrolled in a prospective, randomized, placebo-controlled crossover study. Patients were randomized to one of two doses of intravenous dofetilide or placebo. Patients who failed to respond to this initial infusion received a second higher dose infusion of dofetilide. With the initial infusion, six of ten dofetilide patients converted to sinus rhythm compared to one of five placebo patients. After a second infusion of dofetilide for placebo patients and higher dose dofetilide for low dose dofetilide patients, the overall conversion rate was 71% with dofetilide compared with 20% for placebo (P = 0.046). Atrial fibrillation converted to sinus rhythm in 82% of patients who received dofetilide. Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome.
PubMed: 11523612
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001560
Links to Exploration step
pubmed:11523612Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome.</title><author><name sortKey="Krahn, A D" sort="Krahn, A D" uniqKey="Krahn A" first="A D" last="Krahn">A D Krahn</name><affiliation wicri:level="1"><nlm:affiliation>Division of Cardiology, University of Western Ontario, London, Canada. akrahn@julian.uwo.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Cardiology, University of Western Ontario, London</wicri:regionArea></affiliation></author><author><name sortKey="Klein, G J" sort="Klein, G J" uniqKey="Klein G" first="G J" last="Klein">G J Klein</name></author><author><name sortKey="Yee, R" sort="Yee, R" uniqKey="Yee R" first="R" last="Yee">R. Yee</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11523612</idno><idno type="pmid">11523612</idno><idno type="wicri:Area/PubMed/Corpus">001560</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001560</idno><idno type="wicri:Area/PubMed/Curation">001560</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001560</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome.</title><author><name sortKey="Krahn, A D" sort="Krahn, A D" uniqKey="Krahn A" first="A D" last="Krahn">A D Krahn</name><affiliation wicri:level="1"><nlm:affiliation>Division of Cardiology, University of Western Ontario, London, Canada. akrahn@julian.uwo.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Cardiology, University of Western Ontario, London</wicri:regionArea></affiliation></author><author><name sortKey="Klein, G J" sort="Klein, G J" uniqKey="Klein G" first="G J" last="Klein">G J Klein</name></author><author><name sortKey="Yee, R" sort="Yee, R" uniqKey="Yee R" first="R" last="Yee">R. Yee</name></author></analytic><series><title level="j">Pacing and clinical electrophysiology : PACE</title><idno type="ISSN">0147-8389</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Anti-Arrhythmia Agents (administration & dosage)</term><term>Anti-Arrhythmia Agents (therapeutic use)</term><term>Atrial Fibrillation (drug therapy)</term><term>Atrial Fibrillation (etiology)</term><term>Double-Blind Method</term><term>Electrophysiologic Techniques, Cardiac</term><term>Humans</term><term>Infusions, Intravenous</term><term>Male</term><term>Middle Aged</term><term>Phenethylamines (administration & dosage)</term><term>Phenethylamines (therapeutic use)</term><term>Pilot Projects</term><term>Sulfonamides (administration & dosage)</term><term>Sulfonamides (therapeutic use)</term><term>Tachycardia, Atrioventricular Nodal Reentry (drug therapy)</term><term>Tachycardia, Atrioventricular Nodal Reentry (etiology)</term><term>Wolff-Parkinson-White Syndrome (complications)</term><term>Wolff-Parkinson-White Syndrome (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Arrhythmia Agents</term><term>Phenethylamines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Arrhythmia Agents</term><term>Phenethylamines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Wolff-Parkinson-White Syndrome</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Atrial Fibrillation</term><term>Tachycardia, Atrioventricular Nodal Reentry</term><term>Wolff-Parkinson-White Syndrome</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Atrial Fibrillation</term><term>Tachycardia, Atrioventricular Nodal Reentry</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Double-Blind Method</term><term>Electrophysiologic Techniques, Cardiac</term><term>Humans</term><term>Infusions, Intravenous</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pharmacological conversion of arrhythmias in Wolff-Parkinson-White (WPW) syndrome is often frequently undertaken. Current antiarrhythmic drugs used for conversion can be associated with significant side effects and variable efficacy. Fifteen male patients (mean age 34, range 18-63 years) with WPW syndrome and atrial fibrillation or AVRT induced in the electrophysiology laboratory were enrolled in a prospective, randomized, placebo-controlled crossover study. Patients were randomized to one of two doses of intravenous dofetilide or placebo. Patients who failed to respond to this initial infusion received a second higher dose infusion of dofetilide. With the initial infusion, six of ten dofetilide patients converted to sinus rhythm compared to one of five placebo patients. After a second infusion of dofetilide for placebo patients and higher dose dofetilide for low dose dofetilide patients, the overall conversion rate was 71% with dofetilide compared with 20% for placebo (P = 0.046). Atrial fibrillation converted to sinus rhythm in 82% of patients who received dofetilide. Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11523612</PMID><DateCreated><Year>2001</Year><Month>08</Month><Day>28</Day></DateCreated><DateCompleted><Year>2001</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0147-8389</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>8 Pt 1</Issue><PubDate><Year>2001</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Pacing and clinical electrophysiology : PACE</Title><ISOAbbreviation>Pacing Clin Electrophysiol</ISOAbbreviation></Journal><ArticleTitle>A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome.</ArticleTitle><Pagination><MedlinePgn>1258-60</MedlinePgn></Pagination><Abstract><AbstractText>Pharmacological conversion of arrhythmias in Wolff-Parkinson-White (WPW) syndrome is often frequently undertaken. Current antiarrhythmic drugs used for conversion can be associated with significant side effects and variable efficacy. Fifteen male patients (mean age 34, range 18-63 years) with WPW syndrome and atrial fibrillation or AVRT induced in the electrophysiology laboratory were enrolled in a prospective, randomized, placebo-controlled crossover study. Patients were randomized to one of two doses of intravenous dofetilide or placebo. Patients who failed to respond to this initial infusion received a second higher dose infusion of dofetilide. With the initial infusion, six of ten dofetilide patients converted to sinus rhythm compared to one of five placebo patients. After a second infusion of dofetilide for placebo patients and higher dose dofetilide for low dose dofetilide patients, the overall conversion rate was 71% with dofetilide compared with 20% for placebo (P = 0.046). Atrial fibrillation converted to sinus rhythm in 82% of patients who received dofetilide. Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krahn</LastName><ForeName>A D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of Western Ontario, London, Canada. akrahn@julian.uwo.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>G J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pacing Clin Electrophysiol</MedlineTA><NlmUniqueID>7803944</NlmUniqueID><ISSNLinking>0147-8389</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010627">Phenethylamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>R4Z9X1N2ND</RegistryNumber><NameOfSubstance UI="C063533">dofetilide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000889" MajorTopicYN="N">Anti-Arrhythmia Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022062" MajorTopicYN="N">Electrophysiologic Techniques, Cardiac</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010627" MajorTopicYN="N">Phenethylamines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013611" MajorTopicYN="N">Tachycardia, Atrioventricular Nodal Reentry</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014927" MajorTopicYN="N">Wolff-Parkinson-White Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>8</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>8</Month><Day>29</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11523612</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001560 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001560 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:11523612
|texte= A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:11523612" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |